Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4006896 in Healthy Participants and Participants With Parkinson's Disease
NCT06809400Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LY4006896 in Parkinson's disease (PD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Serious Adverse Event(s) at 48 weeks and Number of Participants with One or More Treatment-Emergent Adverse Events at 48 weeks. Started Feb 2025; status: recruiting.
02
Drugs
LY4006896
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06809400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809400.